Morgan Stanley Call 160 6MK 16.01.../ DE000MB9TCL6 /
11/11/2024 14:46:49 | Diferencia-0.010 | Bid19:29:36 | Ask19:29:36 | Subyacente | Precio de ejercicio | Fecha de expiración | Tipo de opción |
---|---|---|---|---|---|---|---|
0.069EUR | -12.66% | 0.073 Volumen de oferta: 150,000 |
0.079 Tamaño/ Volumen/ Formato de Ask: 150,000 |
MERCK CO. D... | 160.00 - | 16/01/2026 | Call |
GlobeNewswire
31/07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17/07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
09/07
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination ...
GlobeNewswire
25/06
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
06/03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
- Primera página
- Atrás
- 1
- 2
- 3
- 4
- Siguiente
- Última página